Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave® Bioscience, Inc., announced that it plans to conduct an observational, real-world study with Biogen (Nasdaq: BIIB) as the sponsor.

Octave® Bioscience, Inc. Announces Real-World Study Using its Multimodal Precision Care Solution for Multiple Sclerosis Patient Management

Biogen Inc. BIIB said Wednesday it has appointed Dr. Jane Grogan as head of research, effective Oct. 2. Grogan was most recently chief scientific officer at Graphite Bio, a cell and gene editing company.

Biogen names Dr. Jane Grogan head of research effective Oct. 2

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023. Dr. Grogan will be a member of Biogen's Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer.

Biogen Appoints Jane Grogan as Head of Research

While most of Biogen's (BIIB) key drugs are facing declining sales, new products, like Leqembi in Alzheimer's disease, Qalsody in amyotrophic lateral sclerosis and zuranolone in depression, can help revive growth.

Biogen's (BIIB) Stock Outperforms Industry YTD: Here's Why

Biogen receives FDA approval for Leqembi, a treatment for Alzheimer's Disease, providing a large market opportunity. Biogen's acquisition of Reata Pharmaceuticals brings the potential for significant sales growth with SKYCLARYS, a drug for Friedreich's Ataxia. Biogen's pipeline includes Cemdomespib, a potential treatment for diabetic peripheral neuropathy, offering another large market opportunity.

Biogen: Leqembi Could Boost Prospects Until Acquisition Comes Into Play

Eli Lilly

Biogen is adding new products to its lineup to reverse its recent revenue decreases. Eli Lilly has a solid portfolio and strong pipeline, and pays a consistent dividend.

Better Buy: Biogen vs. Eli Lilly

Reata Pharmaceuticals

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Reata Pharmaceuticals, Inc. (NasdaqGM: RETA) to Biogen Inc. (NasdaqGS: BIIB). Under the terms of the proposed transaction, shareholders of Reata will receive $172.50 in cash for each share of Reata that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate.

REATA PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Reata Pharmaceuticals, Inc. - RETA

Biogen Inc. BIIB, -0.90% shares slipped in the extended session Thursday after the Food and Drug Administration granted a soon-to-be Novartis AG NVS, -1.94% spinoff approval for the first biosimilar treatment of multiple sclerosis. The FDA granted approval to Sandoz Inc. for Tyruko, or natalizumab-sztn, the first biosimilar to Biogen's Tysabri, or natalizumab, to treat adults with relapsing forms of MS, and adult patients with moderately to severely active Crohn's Disease.

Biogen stock slips after FDA approves first biosimilar to Tysabri MS treatment

Disc Medicine Inc

NVIDIA

Super Micro Computer

Reata Pharmaceuticals stock gained 345% this year through Friday and is a top 2023 stock.

These Are The 5 Best Stocks Of The Year; Some You May Not Recognize

Spotify

BioCryst Pharmaceuticals

Bank of New York Mellon

Harley-Davidson

Quaker Chemical

Lazard

Scotts Miracle-Gro

TreeHouse Foods

United Continental Hlds

Barron's looked at stocks in the Russell 3000 that have done little for the past five years and identified 10 stocks where improving analyst sentiment could signal better days ahead.

Harley, Spotify, and 8 Other Dead Money Stocks That Are Poised to Come Alive

Biogen recently announced plans to acquire Reata Pharmaceuticals. The deal would give Biogen a potential blockbuster drug in Skyclarys.

Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?

Biogen's planned acquisition will add an important product to its portfolio. The company's new Alzheimer's treatment should help it return to growth, too.

With an Acquisition on the Way, Is Biogen Stock a Buy?

SAGE Therapeutics

The U.S. drug regulator's approval of Biogen and Sage Therapeutics' first-of-its-kind postpartum depression (PPD) pill is unlikely to allay the drugmakers' growth concerns, analysts said on Monday.

Biogen, Sage face uphill battle with postpartum depression pill

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAETM (zuranolone) 50 mg for adults with postpartum depression (PPD). ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women with PPD. ZURZUVAE is expected to launch and be commercially available in the fourth quarter of 2023 shortly following sc.

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day 45

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

The Food and Drug Administration late Friday approved the first-ever pill that can be taken at home for postpartum depression.

FDA approves first-ever pill for postpartum depression in new mothers

The U.S. Food and Drug Administration on Friday approved Biogen and Sage Therapeutics' oral pill for two common forms of depression, paving the way for patients to get a faster-acting therapy to treat their mood disorders.

US FDA approves Biogen-Sage Therapeutics pill for clinical depression

REATA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Reata Pharmaceuticals, Inc. - RETA

CRISPR Therapeutics

Moderna

Medical stocks, in general, aren't enjoying the market-wide reversal we're seeing in the back half of 2023. The Morningstar US Healthcare Index, which measures a range of biotech, pharma, medical device and healthcare facility companies, has returned less than 1% since January.

3 ‘Strong Buy' Biotech Stocks You Should Be Loading Up On Now

Gilead Sciences

Regeneron Pharmaceuticals

The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%.

Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points

Biogen's revenue has been on the decline as the company relies on older products that are losing exclusivity. The acquisition of Reata Pharmaceuticals offers Biogen a new product that could help drive future growth -- and it fits right into Biogen's areas of expertise.

Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.

Biogen and Eli Lilly are two major competitors in the field of Alzheimer's disease. Eli Lilly's medicine appears to slow the rate of cognitive decline more than Biogen's.

Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen

The decision to buy Reata signals a new era under CEO Chris Viehbacher, and Wall Street's skepticism presents an opportunity.

Biogen's New Boss Is Delivering, but Stock Isn't Pricing It in Yet

Exelixis

Illumina

As biotech stock prices have fallen, Wall Street and biotech boards have grown increasingly unfriendly. Amid the turmoil, key biotech stocks have become the targets of activist investors demanding new executives, new boards and new strategies.

Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil

Cincinnati Financial

Enphase Energy

Ford Motor Company

Intel

U.S. equities rallied on Friday, July 28, 2023 after a report showing inflation cooled in June, and the S&P 500 rose 1%.

News for Biogen Stock (BIIB)